These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20035702)

  • 1. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
    Biot J; Fasano C; Dos Santos C
    Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cancer drug shows promise, at a price that many can't pay.
    Berenson A
    N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab, osteoporosis, and prevention of fractures.
    Blythe SL
    N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs: budget busters or cost cutters in future health care?
    Egger E
    Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: denosumab, Amgen.
    Abrahamsen B; Teng AY
    Curr Opin Mol Ther; 2005 Dec; 7(6):604-10. PubMed ID: 16370384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
    Obradovic M; Mrhar A; Kos M
    Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 10. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genentech caps cost of cancer drug for some patients.
    Pollack A
    N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
    [No Abstract]   [Full Text] [Related]  

  • 13. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
    Fuller RL; Goldfield N
    J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection of hope.
    Elliott M
    Nurs Stand; 2010 Nov 10-16; 25(10):23. PubMed ID: 21155482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are mAbs different?: a comment on Cohen and Wilson.
    Neumann PJ
    MAbs; 2009; 1(1):29-30. PubMed ID: 20046571
    [No Abstract]   [Full Text] [Related]  

  • 18. Market watch : Pharma industry strategic performance: 2007-2012E.
    Goodman M
    Nat Rev Drug Discov; 2008 Dec; 7(12):967. PubMed ID: 19043444
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient priority in the era of patent expiries.
    The Lancet Oncology
    Lancet Oncol; 2014 Sep; 15(10):1039. PubMed ID: 25186040
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharma Pricing & Market Access Europe 2016--Health Network Communications' Tenth Annual Conference (February 23-25, 2016--London, UK).
    D'Souza P
    Drugs Today (Barc); 2016 Mar; 52(3):203-6. PubMed ID: 27186595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.